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We previously showed that majority of primary care patients with clinical HF diagnosis had documentation of meeting Framingham criteria for HF at 
least 3 months prior to clinical diagnosis; with 20% meeting criteria at least 2 years prior. We sought to determine the extent to which sophisticated 
data & text mining tools could be used with EHR data to promote use of evidence based therapies for HF management, months to years prior to 
clinical diagnosis.
Incident HF cases (n=4644) from a large primary care practice were identified & stratified into 2 groups (Table 1). Absolute and relative change in 
use of outcome based (ACEI/ARBs, B-blockers) & symptomatic (loop diuretic & digoxin) HF therapies were evaluated within 180 days preceding & 
following the time at which a patient was identified as meeting Framingham criteria, & after being clinically diagnosed with HF.
Patients met Framingham criteria for HF diagnosis, a mean 708 days (median 612) prior to clinical diagnosis. After meeting Framingham criteria, 
absolute increase in use of ACEIs/ARBs was only 9.6% whereas following clinical diagnosis their use increased by 17.9%. Similar changes were seen 
for B-blockers. Loop diuretic use increased by 10.6% after criteria but by 36.6% after clinical diagnosis.
Applying automated text & data mining of EHRs for HF signs & symptoms has the potential to significantly improve care by informing physicians and 
triggering the earlier initiation of therapies proven to improve mortality & minimize HF symptoms & hospitalizations.
Medication usage documented within 6 months of achieving a Framingham and/or Clinical HF diagnosis
Proven Heart Failure Medical 
Treatments
Percentage Receiving Treatment at the time of Clinical Contact
Group A
Patients who met Framingham Criteria 6 months prior to clinical 
diagnosis of HF
(n=3168)
Group B
Patients who did not meet Framingham Criteria 
6 months prior to clinical diagnosis of HF 
(n=1476)
Preceding Framingham 
diagnosis
After Framingham 
diagnosis
After clinical 
diagnosis
Preceding clinical 
diagnosis
After clinical diagnosis
ACE Inhibitor 29.45% 36.46% 50.32% 35.98% 64.97%
Angiotensin Receptor Blocker 8.40% 10.95% 15.03% 9.49% 19.11%
HF -blockers (carvedilol, 
metoprolol succinate, or 
bisoprolol)
37.47% 48.42% 66.51% 48.78% 74.53%
Contra-indicated CCBs 
(diltiazem or verapamil)
18.40% 23.20% 28.44% 20.87% 34.42%
Loop diuretic 18.81% 29.45% 66.07% 31.44% 73.51%
Digoxin 6.34% 8.43% 15.47% 4.00% 25.14%
